[Surveillance and complications of antituberculosis chemotherapy].
D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D003875:Drug Eruptions; D004342:Drug Hypersensitivity; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D008099:Liver / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011605:Psychoses, Substance-Induced; D012216:Rheumatic Diseases / Q000139:chemically induced; D012293:Rifampin / Q000009:adverse effects; D013307:Streptomycin / Q000009:adverse effects; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Surveillance et accidents de la chimiothérapie antituberculeuse.